News | Kayothera

KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate

Sep 18, 2023 | News, Press Release

Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024 Seattle, WA —...

Washington state backs AI-driven cancer diagnostics and other startup projects

Aug 11, 2023 | News

Washington state backs AI-driven cancer diagnostics and other startup projects – GeekWire

KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million

Jul 19, 2023 | News, Press Release

New funding comprised of grants from the National Institutes of Health, The Andy Hill Cancer Research Endowment (CARE) Fund, and additional Equity Funding Additional funding will support advancement of KayoThera’s development programs in diabetes and oncology...

Kayothera Announces Expansion to Type 2 Diabetes with New Pipeline Addition

May 18, 2023 | News

Kayothera, an early-stage therapeutics company developing 1st-in-class, orally-available antagonists of the retinoid pathway, announces that it is advancing a program to treat and reverse cardiometabolic diseases, with a focus on Type 2 Diabetes. The clinical use of...

Kayothera Founder Presented with Princeton University’s Tiger Entrepreneur Award

Oct 18, 2022 | News

Princeton Entrepreneurship Council is pleased to announce the winners of the 2022 Tiger Entrepreneur Award. For the last six years, the Tiger Entrepreneur Award has been given to celebrate the value of entrepreneurship across the Princeton community and to emphasize...

KayoThera, Inc. Raises $8 Million in Series A Financing Led by Accelerator Life Science Partners to Develop Novel Cancer Immunotherapeutics

Mar 16, 2022 | News, Press Release

Novel Approach to Treat Late-Stage and Metastatic Cancers SEATTLE, WA – March 16, 2022, KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing novel cancer immunotherapies, today announces the closing of an $8 million Series A round of...

« Older Entries